vs
Eventbrite, Inc.（EB）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Eventbrite, Inc.的1.7倍（$127.1M vs $73.5M），再鼎医药同比增速更快（17.1% vs -3.9%），再鼎医药自由现金流更多（$-26.7M vs $-60.9M），过去两年再鼎医药的营收复合增速更高（20.8% vs -7.7%）
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
EB vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.7倍
$73.5M
营收增速更快
ZLAB
高出21.0%
-3.9%
自由现金流更多
ZLAB
多$34.2M
$-60.9M
两年增速更快
ZLAB
近两年复合增速
-7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.5M | $127.1M |
| 净利润 | $-8.2M | — |
| 毛利率 | 68.1% | 51.0% |
| 营业利润率 | -12.4% | -54.6% |
| 净利率 | -11.1% | — |
| 营收同比 | -3.9% | 17.1% |
| 净利润同比 | 2.5% | — |
| 每股收益（稀释后） | $-0.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBZLAB
| Q4 25 | $73.5M | $127.1M | ||
| Q3 25 | $71.7M | $115.4M | ||
| Q2 25 | $72.8M | $109.1M | ||
| Q1 25 | $73.8M | $105.7M | ||
| Q4 24 | $76.5M | $108.5M | ||
| Q3 24 | $77.8M | $101.8M | ||
| Q2 24 | $84.6M | $100.1M | ||
| Q1 24 | $86.3M | $87.1M |
净利润EBZLAB
| Q4 25 | $-8.2M | — | ||
| Q3 25 | $6.4M | $-36.0M | ||
| Q2 25 | $-2.1M | $-40.7M | ||
| Q1 25 | $-6.6M | $-48.4M | ||
| Q4 24 | $-8.4M | — | ||
| Q3 24 | $-3.8M | $-41.7M | ||
| Q2 24 | $1.1M | $-80.3M | ||
| Q1 24 | $-4.5M | $-53.5M |
毛利率EBZLAB
| Q4 25 | 68.1% | 51.0% | ||
| Q3 25 | 67.9% | 59.5% | ||
| Q2 25 | 67.5% | 60.6% | ||
| Q1 25 | 66.9% | 63.6% | ||
| Q4 24 | 68.2% | 61.5% | ||
| Q3 24 | 68.5% | 64.1% | ||
| Q2 24 | 70.9% | 64.9% | ||
| Q1 24 | 71.0% | 61.4% |
营业利润率EBZLAB
| Q4 25 | -12.4% | -54.6% | ||
| Q3 25 | -1.3% | -42.3% | ||
| Q2 25 | -8.7% | -50.3% | ||
| Q1 25 | -13.2% | -53.3% | ||
| Q4 24 | -10.2% | -62.6% | ||
| Q3 24 | -11.5% | -66.6% | ||
| Q2 24 | -7.6% | -76.0% | ||
| Q1 24 | -8.8% | -80.7% |
净利率EBZLAB
| Q4 25 | -11.1% | — | ||
| Q3 25 | 8.9% | -31.2% | ||
| Q2 25 | -2.9% | -37.3% | ||
| Q1 25 | -9.0% | -45.8% | ||
| Q4 24 | -11.0% | — | ||
| Q3 24 | -4.8% | -40.9% | ||
| Q2 24 | 1.3% | -80.2% | ||
| Q1 24 | -5.2% | -61.4% |
每股收益（稀释后）EBZLAB
| Q4 25 | $-0.08 | $-0.05 | ||
| Q3 25 | $0.06 | $-0.03 | ||
| Q2 25 | $-0.02 | $-0.04 | ||
| Q1 25 | $-0.07 | $-0.04 | ||
| Q4 24 | $-0.09 | $-0.09 | ||
| Q3 24 | $-0.04 | $-0.04 | ||
| Q2 24 | $0.01 | $-0.08 | ||
| Q1 24 | $-0.05 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.9M | $689.6M |
| 总债务越低越好 | $144.4M | — |
| 股东权益账面价值 | $179.1M | $715.5M |
| 总资产 | $647.2M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.81× | — |
8季度趋势，按日历期对齐
现金及短期投资EBZLAB
| Q4 25 | $299.9M | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | $441.5M | $779.7M | ||
| Q3 24 | $24.7M | $616.1M | ||
| Q2 24 | $56.7M | $630.0M | ||
| Q1 24 | $113.7M | $650.8M |
总债务EBZLAB
| Q4 25 | $144.4M | — | ||
| Q3 25 | $174.9M | — | ||
| Q2 25 | $241.3M | — | ||
| Q1 25 | $241.0M | — | ||
| Q4 24 | $240.7M | — | ||
| Q3 24 | $240.4M | — | ||
| Q2 24 | $358.7M | — | ||
| Q1 24 | $358.2M | — |
股东权益EBZLAB
| Q4 25 | $179.1M | $715.5M | ||
| Q3 25 | $189.1M | $759.9M | ||
| Q2 25 | $177.2M | $791.7M | ||
| Q1 25 | $173.3M | $810.8M | ||
| Q4 24 | $170.2M | $840.9M | ||
| Q3 24 | $179.8M | $667.7M | ||
| Q2 24 | $176.2M | $704.2M | ||
| Q1 24 | $184.1M | $762.2M |
总资产EBZLAB
| Q4 25 | $647.2M | $1.2B | ||
| Q3 25 | $744.6M | $1.2B | ||
| Q2 25 | $784.1M | $1.2B | ||
| Q1 25 | $812.3M | $1.2B | ||
| Q4 24 | $752.3M | $1.2B | ||
| Q3 24 | $817.4M | $985.3M | ||
| Q2 24 | $894.5M | $987.4M | ||
| Q1 24 | $952.2M | $988.4M |
负债/权益比EBZLAB
| Q4 25 | 0.81× | — | ||
| Q3 25 | 0.92× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 2.04× | — | ||
| Q1 24 | 1.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-60.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-60.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | -82.8% | -21.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $17.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流EBZLAB
| Q4 25 | $-60.8M | $-26.0M | ||
| Q3 25 | $36.7M | $-32.0M | ||
| Q2 25 | $-17.5M | $-31.0M | ||
| Q1 25 | $59.4M | $-61.7M | ||
| Q4 24 | $-45.3M | $-55.8M | ||
| Q3 24 | $44.6M | $-26.8M | ||
| Q2 24 | $-32.3M | $-42.2M | ||
| Q1 24 | $68.6M | $-90.1M |
自由现金流EBZLAB
| Q4 25 | $-60.9M | $-26.7M | ||
| Q3 25 | $36.6M | $-35.0M | ||
| Q2 25 | $-17.5M | $-33.9M | ||
| Q1 25 | $59.4M | $-63.2M | ||
| Q4 24 | $-45.3M | $-58.4M | ||
| Q3 24 | $44.4M | $-28.2M | ||
| Q2 24 | $-32.4M | $-42.9M | ||
| Q1 24 | $68.2M | $-91.1M |
自由现金流率EBZLAB
| Q4 25 | -82.8% | -21.0% | ||
| Q3 25 | 51.1% | -30.4% | ||
| Q2 25 | -24.1% | -31.1% | ||
| Q1 25 | 80.4% | -59.9% | ||
| Q4 24 | -59.2% | -53.8% | ||
| Q3 24 | 57.1% | -27.7% | ||
| Q2 24 | -38.3% | -42.9% | ||
| Q1 24 | 79.1% | -104.5% |
资本支出强度EBZLAB
| Q4 25 | 0.0% | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.4% | 1.1% |
现金转化率EBZLAB
| Q4 25 | — | — | ||
| Q3 25 | 5.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -30.37× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
